Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2021

View Archived Issues

RTX-N109D, a rituximab variant with lower sensitivity to CA125 mediated immunosuppression

SRI-42127 attenuates glial activation in a model of LPS-induced neuroinflammation

Gfap-targeted ASO therapy shows efficacy in rat model of Alexander disease

EIDD-2749 shows broad antiviral activity against RSV, SARS-CoV-2 and related RNA viruses

ED to AD: Viagra associated with lower risk of Alzheimer's disease

Jiangsu Protelight Pharmaceutical & Biotechnology patents amino acid derivatives

Shanghai Litedd presents new nuclear receptor RORgammaT antagonists

New ACSS2 inhibitors discovered at Metabomed

Jiangsu Simcere Pharmaceutical R&D discovers SERDs

Incyte describes new mutant GTPase KRAS inhibitors

Phylex develops SARS-CoV-2 vaccine targeting Delta and Omicron variants

Gritstone and CEPI expand agreement for SAM vaccine to target SARS-CoV-2 Omicron variant

Gb Sciences develops cannabinoid-containing complex mixtures to target CRS in COVID-19

Kaleido and Janssen expand Microbiome Metabolic Therapies collaboration

Spago completes regulatory preclinical program with Tumorad

Alpha Cognition reports preclinical data from ALPHA-1062 intranasal TBI program

Bsense reports preclinical data on BSEN-627 in rat pain model

GreenLight and IAVI partner on mRNA vaccine candidate for SARS-CoV-2 Omicron variant

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...